Table 1 Distribution of the investigated pre-treatment characteristics
N patients’ | |
|---|---|
(%) | |
Age | |
≤ 65 years | 332 (48) |
≥ 66 years | 354 (52) |
Interval between initial tumor diagnosis and RT of MSCC | |
≤ 15 months | 395 (58) |
> 15 months | 291 (42) |
Visceral metastases at the time of RT | |
No | 354 (52) |
Yes | 332 (48) |
Other bone metastases at the time of RT | |
No | 237 (35) |
Yes | 449 (65) |
Type of primary tumor | |
Breast cancer | 134 (20) |
Prostate cancer | 140 (20) |
Myeloma/lymphoma | 56 (8) |
Lung cancer | 157 (23) |
Unknown primary | 69 (10) |
Renal cell carcinoma | 41 (6) |
Colorectal cancer | 24 (3) |
Other tumors | 65 (9) |
Gender | |
Female | 265 (39) |
Male | 421 (61) |
Time developing motor deficits prior to RT | |
1–7 days | 228 (33) |
8–14 days | 177 (26) |
> 14 days | 281 (41) |
Gait function prior to RT | |
Not ambulatory | 281 (41) |
Ambulatory | 405 (59) |
Number of vertebrae affected by MSCC | |
1–2 | 279 (41) |
3–4 | 260 (38) |
≥ 5 | 147 (21) |
ECOG performance score | |
1–2 | 317 (46) |
3 | 320 (47) |
4 | 49 (7) |